OGEN vs OLMA

Oragenics Inc. vs Olema Pharmaceuticals, Inc. — Valuation Comparison 2026

OGEN

Pharmaceutical Preparations
Oragenics Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$0.61
Last close
Models
6/13
Active
VS

OLMA

Pharmaceutical Preparations
Olema Pharmaceuticals, Inc.
Quality
5.0
out of 10
Value Trap
18
SAFE
Price
$13.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType OGEN Fair ValueOGEN Upside OLMA Fair ValueOLMA Upside
Bayesian DCF Intrinsic $0.89 +47.2% $4.00 -69.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.14 -76.9% $1.64 -87.5%
Dynamic NAV Asset-Based $4.71 -64.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OGEN vs OLMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OGEN vs OLMA — Which Stock Is More Undervalued?

OLMA scores higher with a 5.0/10 quality rating vs OGEN's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oragenics Inc. (OGEN) and Olema Pharmaceuticals, Inc. (OLMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OGEN currently trades at $0.61 with a QOC of 4.5/10, while OLMA trades at $13.19 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).